ペプチドホルモンの世界市場及びパイプライン分析...市場調査レポートについてご紹介

1. Introduction to HIV Vaccines

2. Issues Related to the Development of HIV Vaccines
2.1 Lack of Antigenicity
2.2 HIV Polymorphism
2.3 High Mutation Rates
2.4 Compromised Immune System
2.5 Integration with DNA

3. Parameters for Successful Commercialization of HIV Vaccines
3.1 Long Term Efficacy
3.2 Reduced Transmission
3.3 Relapse Prevention
3.4 Cost Effectiveness
3.5 Manufacturing Scalability

4. Mechanism of HIV Vaccines

5. Global HIV Vaccines Market Opportunity Analysis
5.1 Market Overview
5.2 HIV Vaccine Clinical Pipeline Overview

6. Global HIV Incidence Rates

7. Global HIV Vaccine Market Dynamics
7.1 Funding Scenario for HIV Vaccine
7.2 Favorable Market Parameters
7.3 HIV Vaccines Commercialization Challenges

8. Global HIV Vaccines Market Future Prospects

9. Global HIV Vaccine Clinical Pipeline by Company & Phase
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
9.8 Preregistration

10. Discontinued & Suspended HIV Vaccines in Clinical Pipeline by Company & Phase
10.1 Discontinued
10.2 Suspended
10.3 No Development Reported

11. Competitive Landscape
11.1 AlphaVax
11.2 Antigen Express
11.3 Argo Therapeutics
11.4 Bionor Pharmaceuticals
11.5 Celldex Therapeutics
11.6 FIT Biotech
11.7 Crucell Pharmaceutical
11.8 GeneCure
11.9 Genetic Immunity
11.10 GenVec
11.11 GeoVax Labs
11.12 Glaxo Smithkline
11.13 Immune Response BioPharma
11.14 Inovio Pharmaceuticals
11.15 Novartis
11.16 Oncolys Biopharma
11.17 PaxVax
11.18 Profectus Biosciences
11.19 Sanofi
11.20 TVAX Biomedical